54121.1 IP-LS

Résumé

alphaRep-HR2 entry inhibitors and a non-antigenic test for the treatment and diagnosis of COVID-19

Textes supplémentaires

Abstract

The SARS-CoV2 pandemic is a major health, economic and societal issue worldwide. Despite the advent of vaccines, novel therapeutic and diagnostic options are needed. Here, we wish to use S artificial nanoligands to develop novel potent entry inhibitors and a non-antigenic test for massive screening.

Participants

Origène Nyanguile

Kontaktperson

origene.nyanguile@hevs.ch

HES-SO Valais-Wallis Origène Nyanguile Route du Rawyl 64 1950 Sion VS CH

Détails du projet

Office de recherche: INNOSUISSE
Statut du projet: Abgeschlossen
Type de projet: Forschungsprojekt
Date de début: 2021-05-31
Date de fin: 2022-12-31
Coûts totaux approuvés: CHF 352488.60
Section: 60 Life Sciences
Domaine politique NABS: Industrielle Produktivität und Technologie

Disciplines de recherche

T410 Pharmaceuticals and related technologies 100.0%